# RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS

> **NCT03979456** · PHASE3 · UNKNOWN · sponsor: **Karolinska Institutet** · enrollment: 200 (estimated)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03979456
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-04
- **Primary completion:** 2024-12-20
- **Final completion:** 2025-06-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2021-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03979456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03979456, "RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03979456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*